Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of Anidulafungin (Ecalta) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery.

Next Previous
Trial Profile

Pharmacokinetics of Anidulafungin (Ecalta) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anidulafungin (Primary)
  • Indications Mycoses
  • Focus Pharmacokinetics
  • Acronyms ADOPT

    • Most Recent Events

    • 03 May 2016 Results published in the Clinical Pharmacokinetics
    • 30 Oct 2014 Last checked against the ClinicalTrials.gov record.
    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top